Canaccord Genuity Starts BioXcel Therapeutics (BTAI) at Buy
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Price: $1.19 +5.31%
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Buy rating and a price target of $21.00.
For an analyst ratings summary and ratings history on BioXcel Therapeutics click here. For more ratings news on BioXcel Therapeutics click here.
Shares of BioXcel Therapeutics closed at $10.24 Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- Curaleaf announces unsolicited takeover bid for Aurora Cannabis
- BMO Capital Starts Energy Fuels (UUUU) at Outperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
